Daratumumab in Treating Patients With Multiple Myeloma

NCT02944565 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Plasma Cell Myeloma

Interventions

BIOLOGICAL: Daratumumab

Sponsor

Ohio State University Comprehensive Cancer Center